Like many global biopharmaceutical companies, AstraZeneca leaned on significant inventory to protect service levels. It worked, but it came at a cost: rising working capital and limited visibility into what was really driving supply decisions.
Partnering with OMP, AstraZeneca rethought its approach, moving to constraint-based planning built around how planners actually work. The result: faster, more confident decisions, less reliance on inventory as a safety net, and a strong co-innovation partnership.
Now, AstraZeneca and OMP are pushing further, extending the planning solution with AI-enabled decision support to free planners to focus on the decisions that matter most.
Mark Trainor, Senior Director of Global Planning, Transformation and Technology, AstraZeneca